CD 133 Gene Polymorphisms as Predictive Markers for Development of Cancer Pancreas
Noha Abd El Razek Kamel Elnakeeb, Rafaat Atta Ibrahim Saad, Tari Magdy Aziz George, Marwa Hassan Mohamed Ahmed, Mostafa Khairy Mohamed Abdelhaleem- General Medicine
Abstract
Background
Pancreatic cancer is one of the most aggressive human malignancies, it ranks the fourth leading cause of cancer death in the Western world and the 13th commonest cancer.
Aim of the Work
The aim of this study is to evaluate the genetic variants CD133 (rs1029728, rs2240688, rs2286455, and rs3130) as possible non-invasive predictive biomarker for Pancreatic cancer in the Egyptian population, this could help to detect the susceptible individuals, diagnose patients earlier, and this improve the therapeutic outcome.
Patients and Methods
This study was conducted in co-operation between Gastroenterology and Hepatology Department, Ain-Shams University and the Gastroenterology and Hepatology Department, Theodor Bilharz Research Institute “between” september 2020 to march 2021. It included total participants of 133
Results
Our study demonstrated that there are three gene polymorphisms showed significant increase in pancreatic cancer group vs. control group, rs2240688 (TT) (65.5%) vs. (44.9%), rs1029728 (AA) (20.2%) vs. (2.0%), and rs3130 (TT) (32.1%) vs. (16.3%) respectively. There is significant increase in rs2240688 (TT), rs1029728 (AG) and rs3130 (TT) with smoking in pancreatic cancer group. And There is significant increase in males in pancreatic cancer group vs. control group in rs3130 (TT) with rs2240688 (TT) polymorphism. While rs2286455 showed no statically significance. The functional polymorphisms rs3130 (CC) and rs2240688 (CC) were found to be higher in control group vs. pancreatic cancer group that may represent a protective value against the disease. So, CD133 gene polymorphisms, rs2240688 (TT) rs1029728 (AA) and rs3130 (TT) could be used as a predictive marker for Pancreatic cancer after validation by larger studies or met analysis.
Conclusion
We concluded that the Genetic polymorphisms of the CD133 gene were associated with risk of Pancreatic cancer are three polymorphisms and represented as rs2240688 (TT) (65.5%) vs. (44.9%), rs1029728 (AA) (20.2%) vs. (2.0%), and rs3130 (TT) (32.1%) vs. (16.3%) Vs. control group. There is significant increase in rs2240688 (TT), rs1029728 (AG) and rs3130 (TT) with smoking in pancreatic cancer group vs. control group. rs3130 (TT) with rs2240688 (TT) gene polymorphisms showed significant increase in pancreatic cancer group group vs. control in male gender only as. According to the age as a demographic variable, mean age for pancreatic cancer group was 61.5 years with percentage of (76.2%) for age more than 50 years vs. (23.8%) for age less than or equal 50 years these. The functional polymorphisms rs3130 (CC) and rs2240688 (CC) were found to be higher in control group vs. pancreatic cancer group that may represent a protective value against the disease.